Organization
Department of Hematology, University Hospitals Leuven and Laboratory of Molecular Immunology (Rega Institute), KU Leuven, Leuven, Belgium
1 abstract
Abstract
Pelabresib (CPI-0610) monotherapy in high-risk essential thrombocythemia refractory or intolerant to hydroxyurea: Preliminary results from MANIFEST study.Org: University of Insubria, Varese, Italy, Hematology Unit, Department of Translational Medicine, University of Eastern Piedmont and AOU Maggiore della Carità, Novara, Italy, Department of Haematology, Division of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff, Wales, United Kingdom, Mayo Clinic Florida, Jacksonville, FL, The Richard T. Silver, M.D. Myeloproliferative Neoplasms Center, Division of Hematology and Oncology, Cornell Medicine, New York, NY,